PUBLISHER: The Business Research Company | PRODUCT CODE: 1427698
PUBLISHER: The Business Research Company | PRODUCT CODE: 1427698
Antimicrobial resistance refers to the phenomenon where microorganisms, including bacteria and fungi, develop the ability to withstand the effects of medications designed to eliminate them. This resistance poses a significant challenge in the treatment of infections and, in severe cases, can lead to fatalities.
The primary classes of drugs associated with antibiotic resistance include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics, characterized by a beta-lactam ring in their chemical structure, work by preventing the construction of bacterial cell walls. They achieve this by covalently binding to crucial penicillin-binding proteins (PBPs), inhibiting the growth of organisms. Pathogens affected by these drugs include Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, among others. These drugs are employed in the treatment of various diseases such as urinary tract infections, intra-abdominal infections, bloodstream infections, and Clostridium difficile infections. The mechanisms of action encompass protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. These drugs are utilized by diverse end-users, including hospitals, homecare, specialty clinics, and more.
The antibiotic resistance market research report is one of a series of new reports from The Business Research Company that provides antibiotic resistance market statistics, including the antibiotic resistance industry global market size, regional shares, competitors with an antibiotic resistance market share, detailed antibiotic resistance market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The antibiotic resistance market size has grown strongly in recent years. It will grow from $11.43 billion in 2023 to $12.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to several factors, including the absence of new antibiotics, the misuse and overuse of antimicrobials in humans, animals, and plants, highly contaminated waste effluents, low vaccination rates, and a lack of diagnostic tools.
The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $15.47 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to factors such as incomplete treatment courses, globalization and travel, poor infection prevention and control, self-medication, cross-species transmission, and high population density. Major trends in the forecast period include technological innovations in drug delivery, global collaboration for surveillance, expanding the role of artificial intelligence, and a surge in novel therapies.
The surge in drug-resistant infections is anticipated to be a significant driver for the expansion of the antibiotic-resistance market. These infections, caused by bacteria resistant to drugs, pose challenges in curing or treating the diseases they cause. Antimicrobial resistance drugs play a crucial role in managing various drug-resistant infections, improving treatment outcomes for both target and non-target pathogens. An example from November 2022, provided by the European Centre for Disease Prevention and Control, highlighted that approximately 35,000 individuals in the EU/EEA succumb annually to antimicrobial-resistant diseases. Furthermore, instances of Klebsiella pneumoniae infections increased by 20% in 2021, and reported cases of Candida auris nearly doubled between 2020 and 2021, emphasizing the driving force behind the antibiotic resistance market due to the prevalence of drug-resistant infections.
The escalation in healthcare expenditure is poised to fuel the growth trajectory of the antibiotic resistance market. Healthcare expenditure denotes the cumulative financial resources invested in healthcare-related goods and services within a specified timeframe. Increased healthcare spending plays a pivotal role in propelling the antibiotic resistance market by fostering heightened research, development, and adoption of innovative treatments to counter the challenges posed by antibiotic-resistant infections. Notably, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, projections indicate an estimated annual growth rate of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, the anticipated annual growth rates of 7.2% for Medicare spending and 5.6% for Medicaid spending from 2021 to 2030 underscore the substantial contribution of growing healthcare expenditure to the expansion of the antibiotic resistance market.
The antibiotic resistance market is witnessing a prominent trend centered on product innovations. Key players within this market are dedicated to pioneering innovative products to solidify their market presence. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical firm, introduced Zidavi. This novel antibiotic, a combination of ceftazidime and avibactam, addresses multi-drug resistant (MDR) infections, ensuring accessibility, affordability, and availability for critically ill patients. Zidavi, available in sterile powdered concentrate for reconstitution, offers a distinctive solution for treating infections caused by MDR gram-negative pathogens. Its formulation in single-dose vials provides an effective alternative for treating hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) linked to meropenem and colistin resistance.
Major enterprises in the antibiotic resistance market are strategically fostering partnerships to innovate and create the next generation of antimicrobial agents alongside practical diagnostics in the fight against Antimicrobial Resistance (AMR). These strategic collaborations involve leveraging complementary strengths and resources to achieve mutual success. For example, in July 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Evotec SE, a German biotechnology firm, joined forces with bioMerieux, a France-based diagnostic solutions provider. This partnership resulted in the formation of Aurobac Therapeutics SAS, aiming to pioneer a novel precision medicine strategy spanning diagnosis to treatment by harnessing the collective expertise of the founding companies. Their collaborative efforts aim to develop innovative antimicrobials coupled with effective diagnostics to counter the challenge posed by Antimicrobial Resistance (AMR).
In July 2022, Innoviva Inc., a pharmaceutical company based in the United States, successfully acquired Entasis Therapeutics Holdings Inc for an undisclosed sum. This strategic acquisition is designed to enhance Innoviva Inc's product portfolio focused on addressing multidrug-resistant gram-negative bacteria, providing a competitive edge in the market. Entasis Therapeutics Holdings Inc., a US-based company, specializes in the development of innovative antibacterial solutions for the treatment of severe bacterial infections resistant to conventional drugs.
Major companies operating in the antibiotic resistance market report are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc., Eppendorf Corporation, Takara Bio Inc., Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics PLC, Seres Therapeutics Inc., Armata Pharmaceuticals Inc.
North America was the largest region in the antibiotic resistance market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Antibiotic Resistance Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on antibiotic resistance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for antibiotic resistance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibiotic resistance market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.